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July 14, 2009

Michele Lumbert, Clerk
Kennebec County Superior Court
95 State Street
Augusta, ME 04330
Re: A ssurance of Discontinuance - Maine Attorney General, Merck
& Co., Inc. Schering-Plough Corporation, MSP Singapore
Company, LLC
Dear Michele:
Enclosed for filing in accordance with 5 M.R.S. § 210, please find
an Assurance of D iscontinuance executed by the Maine Attorney
General, Merck 8s Co., Inc., Schering-Plough Corporation and MSP
Singapore Company, LLC. The A ssurance incorporates the terms of a
Consent Judgm ent entered in S tate of Maine v. Merck & Co., Inc.,
Kennebec County Superior Court Docket No. CV-08-177. Thank you for
your assistan ce in this matter and please do not hesitate to contact me if
you have any questions or concerns.
Sincerely,

CHRISTINA M. MOYLAN
A ssistant Attorney General
2 0 7 /6 2 6 -8 8 3 8
C hristina. m ovlan@ m aine.gov
CMM/s
Enclosure
cc:
Danielle Pelfrey Duryea, Esq.
David Hart, Oregon AAG

ASSURANCE OF DISCONTINUANCE
This Assurance of Discontinuance (''Assurance”) is entered into by the Attorneys General
of Arizona, Arkansas, California, Colorado, Delaware, the District of Columbia, Florida, Hawaii,
Idaho, Illinois, Iowa, Kentucky, Louisiana, Maine, Massachusetts, Michigan, Mississippi,
Missouri, Montana, Nebraska, Nevada, New Jersey, New Mexico, North Carolina, North
Dakota, Ohio, Oregon, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas,
Vermont, Washington, West Virginia, and Wisconsin, acting pursuant to their respective State
Consumer Protection Laws, and Schering-Plough Corporation, Merck & Co., Inc., and MSP
Singapore Company, LLC.
PREAMBLE
WHEREAS, the Multistate Working Group has initiated an investigation of the
Companies with respect to the Covered Conduct;
WHEREAS, the Companies deny that they have engaged in any wrongful or unlawful
conduct;
WHEREAS, the Parties have agreed to resolve the issues raised by the Covered Conduct
by entering into this AVC;
WHEREAS, the Companies have voluntarily cooperated with the investigation and
consented to the entry of this Assurance, and have not admitted any violation of law or finding of
fact;
WHEREAS, no court has entered any findings of fact or conclusions oflaw relating to
this investigation;
IT IS on this 29th day of June, 2009 AGREED, as follows:

DEFINITIONS
1.

“Companies” shall mean Schering, Merck, and MSP collectively.

2.

“Covered Conduct” shall mean the Companies’ promotional and marketing practices
regarding the prescription drags Vytorin® and Zetia®, the Companies’ practices related
to Data Safety Monitoring Boards, the Companies’ publication of clinical trials and
disclosure of clinical trial results, and the Companies’ support of continuing medical
education that were the subject of an investigation by the Signatory Attorneys General
under the State Consumer Protection Laws.

3.

“Effective Date” shall mean the date by which all Parties have executed the Assurance.

4.

“FDA Amendments Act of 2007 (“or FDA Amendments Act” or “the Act”) shall mean
Public Law No. 110-85, which* among other things, creates a federal clinical trial registry
and results data bank.

5.

“FDA’s Guidances for Industry” shall mean documents published by the United States
Department of Health and Human Services, Food and Drug Administration (FDA), that
represent the FDA’s current recommendations on a topic.

6.

“Individual States” and “State” shall mean each Signatory Attorney General who is
participating in the Multistate Working Group.

7.

“Joint Venture(s)” shall mean any entity in which Merck or Schering maintains a direct
and/or indirect ownership interest of 50% or less on the date this Agreement is signed.

8.

“Merck” shall mean Merck & Co:, Inc., and its United States-based affiliates,
subsidiaries, predecessors, successors, and assigns, but shall not include any Joint
Ventures (as that term is defined in the prior subparagraph) except for MSP.
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9.

“MSP" shall mean MSP Singapore Company, LLC.

10.

“Multistate Executive Committee" shall mean the Attorneys General and their staffs
representing Arizona, California, the District of Columbia, Florida, Illinois, New Jersey,
Ohio, Oregon, Pennsylvania, South Carolina, and Texas.

11.

“Multistate Working Group” (“MSWG”) shall mean the Attorneys General and their
staffs representing Arizona, Arkansas, California, Colorado, Delaware, the District of
Columbia, Florida, Hawaii, Idaho, Illinois, Iowa, Kentucky, Louisiana, Maine,
Massachusetts, Michigan, Mississippi, Missouri, Montana, Nebraska, Nevada, New
Jersey, New Mexico, North Carolina, North Dakota, Ohio, Oregon, Pennsylvania, South
Carolina, South Dakota, Tennessee, Texas, Vermont, West Virginia, Washington, and
Wisconsin.

12.

“Parties” shall mean the Companies and the Individual States.

13.

“Product” shall mean any prescription drug or biological product manufactured,
distributed, sold, marketed, or promoted in the United States in any way.

14.

“Schering” shall mean Schering-Plough Corporation and its United States-based
affiliates, subsidiaries, predecessors, successors, and assigns, but shall not include any
Joint Ventures (as that term is defined in the prior subparagraph) except for MSP.

15.

“Signatory Attorney(s) General” shall mean the Attorney General, or his or her designee,
of each state in the Multistate Working Group.

16.

“State Consumer Protection Laws” shall mean the consumer protection laws under which
the Signatory Attorneys General have conducted their investigation.1

1
ARIZONA -A rizona Consumer Fraud Act, A.R.S. § 44-1521 et seqr, ARKANSAS - Arkansas Deceptive
Trade Practices Act, Ark. Code Ann. § 4-88-101, et seqr, CALIFORNIA - Bus. & Prof Code
17200 et seq. and
17500 et seqr, COLORADO - Colorado Consumer Protection Act, Colo. Rev. Stat. § 6-1-101 el seq.; DELAWARE
- Delaware Consumer Fraud Act, Del. CODE ANN. tit. 6, §5 251 1 to 2527; DISTRICT OF COLUMBIA,
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17 .

“Vytorin©” shall mean ezetimibe/simvastatin.

18.

“Zetia©” shall mean ezetimibe or any product that contains ezetimibe other than
Vytorin®.

ASSURANCES
19.

The Companies agree that each of them shall, with respect to the products Vytorin© and
Zetia®, be bound by the provisions contained in Paragraphs 2 through 4 of the Consent
Judgment attached hereto as Exhibit A (hereinafter “Exhibit A”).

20.

The Companies agree that each of them shall, with respect to the products Vytorin© and
Zetia©, be bound by the provisions contained in Paragraph 8 of Exhibit A. The
Companies’ obligations with respect to the provisions contained in Paragraph 8 of
Exhibit A shall remain in effect for six years following the Effective Date. With respect
to the provisions contained in Paragraph 8 of Exhibit A, the Companies shall abide by

Consumer Protection Procedures Act, D.C. Code §§ 28-3901 et seq.; FLORIDA - Florida Deceptive and Unfair
Trade Practices Act, Part II, Chapter 501, Florida Statutes, 501.001 -501.164, 501.207; HAWAII - Uniform
Deceptive Trade Practice Act, Flaw. Rev. Stal. Chpt. 481A and Haw. 501.201 et seq.; IDAHO —Consumer
Protection Act, Idaho Code Section 48-601 et seq.; ILLINOIS - Consumer Fraud and Deceptive Business Practices
Act, 815 ILCS 505/2 et seq:, IOWA - Iowa Consumer Fraud Act, Iowa Code Section 714.16; KENTUCKY Kentucky Consumer Protection Act, KRS Ch. 367.110, et seq.; LOUISIANA - Unfair Trade-Practices and
Consumer Protection Law, LSA-R.S. 51:1401, et seq:, M A IN E- Unfair Trade Practices Act, 5 M.R.S.A. § 207 et
seq:, MASSACHUSETTS - Mass. Gen. Laws c. 93 A, §§ 2 and 4; MICHIGAN —Michigan Consumer Protection
Act, MCL § 445.901 et seq:, MISSISSIPPI - Mississippi Consumer Protection Act, Miss. Code Ann. § 75-24-1 et
seq. (1972 as amended); MISSOURI - Missouri Merchandising Practices Act, Mo. Rev. Stat. §§ 407 et seq.;
MONTANA - Montana Code Annotated 30-14-101 et seq.; NEBRASKA - Uniform Deceptive Trade Practices Act,
NRS §§ 87-301 et seq.; NEVADA - Deceptive Trade Practices Act, Nevada Revised Statutes 598.0903 et seq.;
NEW JERSEY - New Jersey Consumer Fraud Act, NJSA 56:8-1 et seq.; NEW MEXICO - NMSA 1978, § 57-12-1
et seq.; NORTH CAROLINA - North Carolina Unfair and Deceptive Trade Practices Act, N.C.G.S. 75-1,1, et seq.;
NORTH DAKOTA - Unlawful Sales or Advertising Practices, N.D. Cent. Code § 51-15-02 et seq.; O H IO - Ohio
Consumer Sales Practices Act, R.C. 1345.01, et seq.; OREGON - Oregon Unlawful Trade Practices Act, ORS
646.605 et seq.; PENNSYLVANIA - Pennsylvania Unfair Trade Practices and Consumer Protection Law, 73 P.S.
201-1 et seq.; SOUTH CAROLINA - South Carolina Unfair Trade Practices Act, sections 39-5-10 el seq.; SOUTH
DAKOTA —South Dakota Deceptive Trade Practices and Consumer Protection, SDCL ch. 37-24; TENNESSEE Tennessee Consumer Protection Act, Teim. Code Ann. 47-18-101 et seq.; TEXAS —Texas Deceptive Trade
Practices-Consumer Protection Act, Tex. Bus. & Com. Code 17.47, et seq.; VERMONT - Consumer Fraud Act, 9
V.S.A. §§ 2451 et seq.; WASHINGTON - Unfair Business Practices/Consumer Protection Act, RCW §§ 19.86 et
seq.; WEST VIRGINIA - West Virginia Consumer Credit and Protection Act, W. Va. Code § 46A-1 101 et seq.;
WISCONSIN - Wis. Stat. § 100.18 (Fraudulent Representations).
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any such written recommendation when such submission is made within six years of the
Effective Date.
21.

The Companies agree that each of them shall, with respect to the products Vytorin® and
Zetia®, be bound by the provisions contained in Paragraphs 10 through 13 of Exhibit A.
The Companies’ obligations with respect to the provisions contained in Paragraph 13 of
Exhibit A shall remain in effect for eight years following the Effective Date. The
Companies’ obligations with respect to the provisions contained in Paragraph 13(b) of
Exhibit A shall only apply to speakers’ contracts entered into, amended to extend the
contract period, or renewed after the Effective Date.

22.

The Companies agree that each of them shall, with respect to the products Vytorin® and
Zetia®, be bound by the provisions contained in Paragraphs 15 and 17 through 19 of
Exhibit A. The provisions contained in subparagraph 15(d)(ii) of Exhibit A shall also
apply to consulting relationships with Schering-Plough Research Institute. The
Companies’ obligations with respect to the provisions contained in Paragraph 15 of
Exhibit A shall remain in effect for six years following the Effective Date.

23.

Nothing in this Assurance shall require the Companies to:
a. take an action that is prohibited by the FDCA or any regulation promulgated
thereunder, or by FDA; or
b. fail to take an action that is required by the FDCA or any regulation promulgated
thereunder, or by FDA. Any written or oral promotional claim subject to this
Assurance which is the same, or materially the same, as the language required or
agreed to by the Director of DDMAC or the Director of the Center for Drug

-
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Evaluation or their authorized designees in writing shall not constitute a violation of
this Assurance.
24.

All obligations undertaken by the Companies in this Assurance shall apply prospectively,
except, to the extent permitted by the National Library of Medicine, the Companies shall
submit, as soon as practicable, clinical trial results to the clinical trial registry and results
data bank created by the FDA Amendments Act for all “applicable clinical trials” (as that
term is defined by the Act) of Vytorin® and/or Zetia® that were initiated after July 1,
2005.

25.

The Companies shall be bound by the provisions of paragraphs 19 through 24 of this
Assurance beginning 120 days after the Effective Date.

GENERAL PROVISIONS
26.

Release of Claims: By its execution of this Assurance, each Individual State releases the
Companies and all of their past and present subsidiaries, affiliates, predecessors and
successors (collectively, the “Released Parties”) from all civil claims, causes of action,
damages, restitution, fines, costs, and penalties on behalf of the-Individual State under the
consumer protection statutes listed in footnote 1 of this Assurance arising from the
Covered Conduct that is the subject of this Assurance.

27.

Claims Reserved: Notwithstanding any term of the Assurance, specifically reserved and
excluded from the Release in Paragraph 26 as to any entity or person, including Released
Parties, are any and all of the following:
a. Any criminal liability that any person or entity, including Released Parties, has or
may have to any State;

b. Any civil or administrative liability that any person or entity, including Released
Parties, has or may have to any State under any statute, regulation or rule not
expressly covered by the release in Paragraph 26 above, including but not limited to
any and all of the following claims:
i.

State or federal antitrust violations;

ii. Reporting practices, including “best price,” “average wholesale price,” or
“wholesale acquisition cost”;
iii. Medicaid violations, including federal Medicaid drug rebate statute violations,
Medicaid fraud or abuse, and/or kickback violations related to any State’s
Medicaid program; and
iv. State false claims violations.
c. Any liability under the State Consumer Protection Laws which any person or entity,
including Released Parties, has or may have to individual consumers or State program
payors of said State, and which have not been specifically enumerated as included
herein.
28.

Mutual Understanding: The Parties mutually recognize the following:
a. The Companies are entering into this Assurance solely for the purpose of settlement,
and nothing contained herein may be taken as or construed to be an admission or
concession of any violation of law, rule, or regulation, or any other matter of fact or
law, or of any liability or wrongdoing, all of which the Companies expressly deny.
The Companies do not admit any violation of the State Consumer Protection Laws set
forth in footnote 1, and do not admit any wrongdoing that was or could have been
alleged by any Attorney General before the date of the Assurance under those laws.
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No part of this Assurance, including its statements and commitments, shall constitute
evidence of any liability, fault, or wrongdoing by the Companies.
b. This Assurance shall not be construed or used as a waiver or limitation of any defense
otherwise available to the Companies in any action, or of the Companies’ right to
defend themselves from, or make any arguments in, any private individual or class
claims or suits relating to the subject matter or terms of this Assurance. This
Assurance is made without trial or adjudication of any issue of fact or law or finding
of liability of any kind.
c. It is the intent of the Parties that this Assurance not be admissible in other cases or
binding on the Companies in any respect other than in connection with the
enforcement of this Assurance.
d. No part of this Assurance shall create a private cause of action or confer any right to
any third party for violation of any federal or state statute except that a State may file
an action to enforce the terms of this Assurance.
Reimbursement for Investigative Costs: Within ten business days of the Effective Date of
this Assurance, the Companies shall pay a total amount of $5,400,000.00 to the Signatory
Attorneys General. A portion of this amount designated by the Multistate Executive
Committee in the sole discretion of that Committee shall be paid by the Companies
directly to each Signatory Attorney General. Said payments shall be made in
reimbursement of the Multistate Working Group’s attorneys’ fees and other costs of
investigation and shall be put to use as permitted by state law at the sole discretion of
each Signatory Attorney General.

30.

Compliance: For purposes of resolving disputes with respect to compliance with this
Assurance:
a. Should any of the Signatory Attorneys General have a reasonable basis to believe that
the Companies have engaged in a practice that violates a provision of this Assurance
subsequent to the Effective Date of this Assurance, then such Attorney General shall
notify the Companies in writing of the specific objection, identify with particularity
the provisions of this Assurance that the practice appears to violate, and give the
Companies thirty (30) days to respond to the notification; provided, however, that a
Signatory Attorney General may take any action where the Signatory Attorney
General concludes that, because of the specific practice, a threat to the health or
safety of the public requires immediate action.
b. Upon receipt of written notice, the Companies shall provide a good-faith written
response to the Attorney General notification, containing either a statement
explaining why the Companies believe they are in compliance with the Assurance, or
a detailed explanation of how the alleged violation occurred and a statement
explaining how the Companies intend to cure the alleged breach.
c. Upon giving the Companies thirty (30) days to respond to the notification described
above, the Signatory Attorney General shall also be permitted reasonable access to
relevant, non-privileged, non-work product records and documents in the possession,
custody, or control of the Companies that relate to the Companies' compliance with
each provision of this Assurance as to which cause that is legally sufficient in the
State has been shown. If the Signatory Attorney General makes or requests copies of
any documents during the course of that inspection, the Signatory Attorney General

will provide a list of those documents to the Companies. Nothing in this paragraph
shall be interpreted to limit the State’s Civil Investigative Demand ("CID”) or
subpoena authority, to the extent such authority exists under applicable state law, and
the Companies reserve all rights with respect to a CID or subpoena issued pursuant to
such authority.
d. The State may assert any claim that the Companies have violated this Assurance in a
separate civil action to enforce this Assurance, or to seek any other relief afforded by
law, only after providing the Companies an opportunity to respond to the notification
described in Paragraph 30(a) above; provided, however, that a Signatory Attorney
General may take any action where the Signatory Attorney General concludes that,
because of the specific practice, a threat to the health or safety of the public requires
immediate action.
31.

Entire Agreement: This Assurance represents the entire agreement entered into by the
Parties hereto and shall bind the Parties hereto. In any action undertaken by either the
Attorneys General, or any of them, or the Companies, no prior versions of this Assurance,
and no prior versions of any of its terms may be introduced for any purpose whatsoever.

32.

Modification: Any Party to the Assurance may seek modification of the Assurance if it
believes that facts and circumstances underlying the Assurance have changed in any
material respect. The Multistate Executive Committee agrees to coordinate discussions
with the Companies regarding any such modification and to make recommendations to
the Multistate Working Group. This Assurance shall be modified only by mutual assent
of the parties and only by a written instrument, signed by or on behalf of the Parties, and,
where required, by court order. If, after the date of entry of this Assurance, an Individual
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State, its Attorney General, or any agency of an Individual State enacts or promulgates
legislation, rules or regulations with respect to matters governed by this Assurance that
conflict with any provision of this Assurance, or if the applicable law of the Individual
State shall otherwise change so as to conflict with any provision of this Assurance, the
Attorney General shall not unreasonably withhold his or her consent to the modification
of such provision to the extent necessary to eliminate such conflict. Laws, rales, or
regulations, or other changes in Individual State law, with respect to the matters governed
by this Assurance, shall not be deemed to conflict with a provision of this Assurance
unless the Companies cannot reasonably comply with both such law, rule, or regulation
and the applicable provision of this Assurance.
33.

Severability: If any portion of this Assurance is held invalid or unenforceable by
operation of law, the remaining terms of this Assurance shall not be affected.

34.

Certification: The Parties certify that their undersigned representative is fully authorized
to enter into the terms and conditions of this Assurance and to legally bind the party
represented.
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FOR SCHERING-PLOUGH CORPORATION:

Thomas J. Sabatrty/Jr.
Executive Vice President and General Counsel
Schering-Plough Corporation
2000 Galloping Hill Road
Kenilworth, New Jersey 07033
Date:

7/ 7/^7

FOR MERCK & CO., INC.:
/
..<
J,
Bruce N. Kuhlik
Executive Vice President and General Counsel
Merck & Co., Inc.
One Merck Drive
Whitehouse Station, New Jersey 08889

Date:

17

FOR MSP SINGAPORE COMPANY, LLC:

James Grasty
|
Vice Président and Assistant General Counsel
Merck & Co., Inc.
One Merck Drive
Whitehouse Station, New Jersey 08889
Date:

7 "^

a _______________

PD Villarreal
Vice President and Associate General Counsel
Schering-Plough Corporation
2000 Galloping Hill Road
Kenilworth, New Jersey 07033
Date:

-
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Brien T. O’Connor
Joan McPhee
Joshua S. Levy
Ropes & Gray LLP
One International Place
Boston, MA 02110-2624
Counsel to Schering-Plough Corporation,
Merck & Co., Inc., and
MSP Singapore Company LLC

STATE OF MAINE
Attorney General Janet T. Mills

Christina M. Moylan
Assistant Attorney General

Date:

j.

-

13

-

